Global Liquid Biopsy Market - Forecasts from 2019 to 2024

November 2019 | 113 pages | ID: G31C7BDF9261EN
Knowledge Sourcing Intelligence LLP

Abstracts

The global liquid biopsy market is expected to reach $4,380.534 million by 2024 from $1,246.248 million in 2018 growing at a CAGR of 23.31%. Liquid biopsy, also known as fluid biopsy is a non-invasive technique which enables to discover a range of information about a tumour through sampling and analysis of non-solid biological tissue such as blood. The evolution of sensitive technologies have enabled the development of liquid biopsies for various clinical applications including screening for the presence of disease, monitoring treatment response, patient stratification and therapy selection and detection of recurrence or the presence of residual disease after surgery. The growth in the market may be attributed to the rising patient population base owing to the rising prevalence of cancer. Rising preference for the non-invasive procedures will also augment the growth of the liquid biopsy market during the given forecast period. However unclear regulatory scenario pertaining to liquid biopsy along with unfavourable reimbursement policies might restrain the growth of the market during the given time frame.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global liquid biopsy market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global liquid biopsy market.

Major industry players profiled as part of the report are F. Hoffmann-La Roche Ltd , Bio-Rad Laboratories, Inc., Genomic Health

.

Segmentation

By Sample Tissue

• Blood
• Urine
• Saliva
• Others

By Biomarkers

• Circulating Tumor Cells
• Circulating Tumor DNA (CTDNA)
• Neurology E’xtracellular Vesicles (Evs)
• Others

By Application

• Screening
• Disease Prognosis
• Drug Response and Resistance

By Geography

• North America
• United States
• Canada
• Others
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• India
• Australia
• South Korea
• Others

Contents

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TISSUE

5.1. Blood
5.2. Urine
5.3. Saliva
5.4. Others

6. GLOBAL LIQUID BIOPSY MARKET BY BIOMARKERS

6.1. Circulating Tumor Cells
6.2. Circulating Tumor DNA (CTDNA)
6.3. Neurology E’xtracellular Vesicles (Evs)
6.4. Others

7. GLOBAL LIQUID BIOPSY MARKET BY APPLICATION

7.1. Screening and Diagnostics
7.2. Disease Prognosis
7.3. Drug Response and Resistance

8. GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY

8.1. North America
  8.1.1. United States
  8.1.2. Canada
  8.1.3. Mexico
8.2. South America
  8.2.1. Brazil
  8.2.2. Argentina
  8.2.3. Others
8.3. Europe
  8.3.1. United Kingdom
  8.3.2. Germany
  8.3.3. France
  8.3.4. Others
8.4. Middle East and Africa
  8.4.1. Saudi Arabia
  8.4.2. UAE
  8.4.3. Israel
  8.4.4. Others
8.5. Asia Pacific
  8.5.1. China
  8.5.2. India
  8.5.3. Australia
  8.5.4. South Korea
  8.5.5. Others

9. COMPETITIVE INTELLIGENCE

9.1. Company Benchmarking and Analysis
9.2. Recent Investment and Deals
9.3. Strategies of Key Players

10. COMPANY PROFILES

10.1. F. Hoffmann-La Roche Ltd
10.2. Bio-Rad Laboratories, Inc.
10.3. Genomic Health
10.4. QIAGEN
10.5. NeoGenomics Laboratories, Inc.
10.6. OncoCyte Corporation
10.7. Biocept, Inc.
10.8. LungLife AI, Inc.
LIST OF FIGURES
LIST OF TABLES